Robert Wasserman Analyst Performance

Robert Wasserman is a stock analyst at Benchmark in the medical sector, covering 13 publicly traded companies. Over the past year, Robert Wasserman has issued 14 stock ratings, including buy and hold recommendations. While full access to Robert Wasserman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Wasserman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

20 Last 6 Years

Buy Recommendations

95.00% 19 Buy Ratings

Companies Covered

13 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	95.0%	19 ratings
Hold	5.0%	1 ratings
Sell	0.0%	0 ratings

Out of 20 total stock ratings issued by Robert Wasserman at Benchmark, the majority (95.0%) have been Buy recommendations, followed by 5.0% Hold.

Best & Worst Calls

• Best Call

  000.0%

  CSBR

  Nov 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  IDXG

  Oct 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	84.6% of companies on NASDAQ	11 companies
NYSE	15.4% of companies on NYSE	2 companies

Robert Wasserman, an analyst at Benchmark, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	100.0%

Robert Wasserman of Benchmark specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	53.8%
MED - DRUGS 2 companies	15.4%
MED INSTRUMENTS 2 companies	15.4%
MEDICAL INFO SYS 1 company	7.7%
SURGICAL & MEDICAL INSTRUMENTS 1 company	7.7%

About Robert Wasserman

Robert Wasserman is an Equity Research Analyst covering Bioprocessing and Life Sciences companies. Prior to Benchmark, Bob’s 25-plus years of investment experience includes previous equity research positions at Craig-Hallum, Dawson James, Southeast Research Partners, and Jesup & Lamont. He was named an All-Star Analyst in Healthcare by the Wall Street Journal and has been quoted and appeared in financial print and media outlets. Bob holds BS degrees in engineering and management from MIT and an MBA from the University of Chicago.

Follow on LinkedIn

Robert Wasserman's Ratings History at Benchmark

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
HALO Halozyme Therapeutics	9/24/2025	Boost Price Target	$77.57	$90.00	Buy	$0.00 00.00% ROI
LGND Ligand Pharmaceuticals	9/2/2025	Boost Price Target	$163.94	$175.00	Buy	$0.00 00.00% ROI
INTS Intensity Therapeutics	8/20/2025	Lower Price Target	$0.30	$1.50	Speculative Buy	$0.00 00.00% ROI
TECH Bio-Techne	6/5/2025	Reiterated Rating	$49.10	$75.00	Buy	$0.00 00.00% ROI
OABI OmniAb	5/12/2025	Reiterated Rating	$1.47	$6.00	Buy	$0.00 00.00% ROI
TECH Bio-Techne	5/8/2025	Lower Price Target	$48.76	$75.00	Buy	$0.00 00.00% ROI
ITGR Integer	4/25/2025	Lower Price Target	$120.27	$140.00	Buy	$0.00 00.00% ROI
XOMA XOMA Royalty	4/17/2025	Initiated Coverage	$20.53	$35.00	Buy	$0.00 00.00% ROI
IPA ImmunoPrecise Antibodies	4/1/2025	Reiterated Rating	$0.36	$3.00	Speculative Buy	$0.00 00.00% ROI
KMDA Kamada	3/21/2025	Initiated Coverage	$6.65	$15.00	Buy	$0.00 00.00% ROI
OABI OmniAb	3/20/2025	Lower Price Target	$2.45	$6.00	Buy	$0.00 00.00% ROI
ABCL AbCellera Biologics	3/3/2025	Reiterated Rating	$2.50		Hold	$0.00 00.00% ROI
ITGR Integer	2/21/2025	Boost Price Target	$129.11	$150.00	Buy	$0.00 00.00% ROI
HALO Halozyme Therapeutics	2/20/2025	Reiterated Rating	$57.17	$75.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.